Source: http://www.google.com/patents/US5716937?dq=3984803
Timestamp: 2016-07-26 06:36:05
Document Index: 718912339

Matched Legal Cases: ['art 2', 'art 2', 'art 2', 'art 2', 'art 2', 'art 2']

Patent US5716937 - Method for treating cardiac malfunction - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA method of treating cardiac malfunction by administering a positive inotropic effect-producing amount of Hypothalamic Inhibitory factor (HIF)....http://www.google.com/patents/US5716937?utm_source=gb-gplus-sharePatent US5716937 - Method for treating cardiac malfunctionAdvanced Patent SearchPublication numberUS5716937 APublication typeGrantApplication numberUS 08/338,264Publication dateFeb 10, 1998Filing dateNov 10, 1994Priority dateDec 13, 1989Fee statusLapsedAlso published asUS6274558Publication number08338264, 338264, US 5716937 A, US 5716937A, US-A-5716937, US5716937 A, US5716937AInventorsGarner Haupert, Jr.Original AssigneeThe General Hospital CorporationExport CitationBiBTeX, EndNote, RefManPatent Citations (6), Non-Patent Citations (43), Referenced by (14), Classifications (7), Legal Events (5) External Links: USPTO, USPTO Assignment, EspacenetMethod for treating cardiac malfunction
US 5716937 AAbstract
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4551426 *Jan 18, 1984Nov 5, 1985E. I. Du Pont De Nemours And CompanyHeterogeneous immunoassay for digoxin using ouabain as a separation meansUS4665019 *Aug 31, 1983May 12, 1987University Of MarylandMethod for measuring the plasma levels of an inhibitor of (Na+ +K.sup.+US4780314 *Oct 30, 1985Oct 25, 1988Brigham And Women's HospitalIsolation and purification of a digitalis-like factorUS5164296 *Aug 31, 1990Nov 17, 1992University Of Maryland At BaltimoreAssay methods involving ouabainUS5429928 *Jul 28, 1992Jul 4, 1995University Of Maryland At BaltimoreImmunoassay for detecting human ouabainWO1992004047A1 *Aug 21, 1991Mar 19, 1992University Of Maryland At BaltimoreMethods of treating, diagnosing and monitoring therapies from levels of human oubain-like factor and antibody thereof* Cited by examinerNon-Patent CitationsReference1Axelrod, Julius, "J. Methylation Reactions in the Formation and Metabolism of Catecholamines and Other Biogenic Amines," Pharmacological Reviews, 18(1), Part I:95-113 (1966).2 *Axelrod, Julius, J. Methylation Reactions in the Formation and Metabolism of Catecholamines and Other Biogenic Amines, Pharmacological Reviews, 18(1), Part I:95 113 (1966).3Carilli, Cynthia T. et al., "Hypothalamic Factor Inhibits the (Na,K)ATPase from the Extracellular Surface," The Journal of Biological Chemistry, 260(2):1027-1031 (1985).4 *Carilli, Cynthia T. et al., Hypothalamic Factor Inhibits the (Na,K)ATPase from the Extracellular Surface, The Journal of Biological Chemistry, 260(2):1027 1031 (1985).5 *Dermer, Biotechnology, 12: 320, 1994.6 *Foon, Cancer Res, 49: 1621 39, 1989.7Foon, Cancer Res, 49: 1621-39, 1989.8Hallaq, Haifa A. and Haupert, Garner T., Jr., "Positive inotropic effects of the endogenous Na+ /K+ -transporting ATPase inhibitor from the hypothalamus," Proc. Natl. Acad. Sci. USA, 86:10080-10084 (1989).9 *Hallaq, Haifa A. and Haupert, Garner T., Jr., Positive inotropic effects of the endogenous Na /K transporting ATPase inhibitor from the hypothalamus, Proc. Natl. Acad. Sci. USA, 86:10080 10084 (1989).10 *Harris et al., TIBTECH, 11: 42 44, 1993.11Harris et al., TIBTECH, 11: 42-44, 1993.12Haupert, Garner T., Jr. and Sancho, Jose M., "Sodium transport inhibitor from bovine hypothalamus," Proc. Natl. Acad. Sci. USA, 76(9):4658-4660 (1979).13 *Haupert, Garner T., Jr. and Sancho, Jose M., Sodium transport inhibitor from bovine hypothalamus, Proc. Natl. Acad. Sci. USA, 76(9):4658 4660 (1979).14Haupert, Garner T., Jr. et al., "Hypothalamic sodium-transport inhibitor is a high-affinity reversible inhibitor of Na+ -K+ -ATPase," reprint from American Physiological Society:F919-F924 (1984).15 *Haupert, Garner T., Jr. et al., Hypothalamic sodium transport inhibitor is a high affinity reversible inhibitor of Na K ATPase, reprint from American Physiological Society :F919 F924 (1984).16 *Haupert, Jr.; in The Na , K Pump, Part B: Cellular Aspects; Alan R. Liss, Inc., New York; 1988; pp. 297 320.17Haupert, Jr.; in The Na+ , K+ -Pump, Part B: Cellular Aspects; Alan R. Liss, Inc., New York; 1988; pp. 297-320.18Hoffman, Brian F. and Bigger, J. Thomas, Jr. "Chapter 34 Digitalis and Allied Cardiac Glycosides," in The Pharmacological Basics for Therapeutics (NY: Pergamon Press), pp. 814-839 (1990).19 *Hoffman, Brian F. and Bigger, J. Thomas, Jr. Chapter 34 Digitalis and Allied Cardiac Glycosides, in The Pharmacological Basics for Therapeutics (NY: Pergamon Press), pp. 814 839 (1990).20Hunter, Meredith Mudgett et al., "High-Affinity Monboclonal Antibodies to the Cardiac Glycoside, Digoxin," The Journal of Immunology, 129(3):1165-1172 (1982).21 *Hunter, Meredith Mudgett et al., High Affinity Monboclonal Antibodies to the Cardiac Glycoside, Digoxin, The Journal of Immunology, 129(3):1165 1172 (1982).22J.M. Hamlyn et al., "Identification and characterization of a ouabainlike compound from human plasma," Proc. Natl. Acad. Sci. USA 88:6259-6263, Jul. 1991.23 *J.M. Hamlyn et al., Identification and characterization of a ouabainlike compound from human plasma, Proc. Natl. Acad. Sci. USA 88:6259 6263, Jul. 1991. 24James H. Ludens et al., "Purification of an Endogenous Digitalislike Factor From Human Plasma for Structural Analysis," Hypertension 17(6) Part 2, pp. 923-929, Jun. 1991.25 *James H. Ludens et al., Purification of an Endogenous Digitalislike Factor From Human Plasma for Structural Analysis, Hypertension 17(6) Part 2, pp. 923 929, Jun. 1991.26Janssens, Stefan P. et al., "Hypothalamic Na30, K30 -ATPase Inhibitor Constricts Pulmonary Arteries of Spontaneously Hypertensive Rats," Journal of Cardiovascular Pharmacology, 22(Suppl. 2):S42-S46 (1993).27 *Janssens, Stefan P. et al., Hypothalamic Na 30 , K 30 ATPase Inhibitor Constricts Pulmonary Arteries of Spontaneously Hypertensive Rats, Journal of Cardiovascular Pharmacology, 22(Suppl. 2):S42 S46 (1993).28Mirsalikhova, N.M. et al., "Some Features of the Inhibition of Na30 ,K30 -ATPase in Heart Muscle by Cardiotonic Glycosides," Institute of Biochemistry and Institute of Chemistry of Plant Substances, Academy of Sciences and the Urbek SSR, Tashkent, USSR, pp. 269-275.29 *Mirsalikhova, N.M. et al., Some Features of the Inhibition of Na 30 ,K 30 ATPase in Heart Muscle by Cardiotonic Glycosides, Institute of Biochemistry and Institute of Chemistry of Plant Substances, Academy of Sciences and the Urbek SSR, Tashkent, USSR, pp. 269 275.30 *Mudgett Hunter, Meredith et al., Binding and Structural Diversity Among High Affinity Monoclonal Anti Digoxin Antibodies, Molecular Immunology, 22(4):477 488 (1985).31Mudgett-Hunter, Meredith et al., "Binding and Structural Diversity Among High-Affinity Monoclonal Anti-Digoxin Antibodies," Molecular Immunology, 22(4):477-488 (1985).32Sergio Bova, et al., "Effects of an Endogenous Ouabainlike Compound on Heart and Aorta," Hypertension 17(6), Part 2 pp. 944-950, Jun. 1991.33 *Sergio Bova, et al., Effects of an Endogenous Ouabainlike Compound on Heart and Aorta, Hypertension 17(6), Part 2 pp. 944 950, Jun. 1991.34Smith, Thomas W. et al., "Reversal of Advances Digoxin Intoxication with Fab Fragments of Digoxin-Specific Antibodies," The New England Journal of Medicine, 294(15):797-800 (19767).35Smith, Thomas W. et al., "Treatment of Life-Threatening Digitalis Intoxication with Digoxin-Specific Fab Antibody Fragments," The New England Journal of Medicine, 307(22):1357-131362 (1982).36 *Smith, Thomas W. et al., Reversal of Advances Digoxin Intoxication with Fab Fragments of Digoxin Specific Antibodies, The New England Journal of Medicine, 294(15):797 800 (19767).37 *Smith, Thomas W. et al., Treatment of Life Threatening Digitalis Intoxication with Digoxin Specific Fab Antibody Fragments, The New England Journal of Medicine, 307(22):1357 131362 (1982).38Thomas, Richard et al., "Synthesis and Biological Activity of Semisynthetic Digitalis Analogs," Journal of Pharmaceutical Sciences, 63(11):1649-1683 (1974).39 *Thomas, Richard et al., Synthesis and Biological Activity of Semisynthetic Digitalis Analogs, Journal of Pharmaceutical Sciences, 63(11):1649 1683 (1974).40W. Rodney Mathews et al., "Mass Spectral Characterization of an Endogenous Digitalislike Factor From Human Plasma," Hypertension 17(6), Part 2, pp. 930-935, Jun. 1991.41 *W. Rodney Mathews et al., Mass Spectral Characterization of an Endogenous Digitalislike Factor From Human Plasma, Hypertension 17(6), Part 2, pp. 930 935, Jun. 1991.42 *Waldmann, Science, 252: 1657 1662, 1991.43Waldmann, Science, 252: 1657-1662, 1991.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5910484 *May 30, 1997Jun 8, 1999The General Hospital CorporationTreatment of ischemic cardiac malfunctionUS6265383 *Jun 7, 1999Jul 24, 2001The General Hospital CorporationTreatment of ischemic cardiac malfunctionUS6846646Dec 24, 1998Jan 25, 2005The General Hospital CorporationMethods for screening HIF like ouabain-resistant Na+-K+-ATPase agentsUS6998470Feb 17, 2000Feb 14, 2006Bion, Inc.Process for large-scale isolation and purification of hypothalamic inhibitory factorUS7155284Jan 16, 2003Dec 26, 2006Advanced Bionics CorporationTreatment of hypertensionUS7308303Nov 1, 2002Dec 11, 2007Advanced Bionics CorporationThrombolysis and chronic anticoagulation therapyUS7348412Oct 5, 1999Mar 25, 2008The General Hospital CorporationOuabain-specific monoclonal antibodiesUS7396658Mar 16, 2004Jul 8, 2008The General Hospital CorporationMethods for screening HIF like ouabain-resistant Na+—K+-ATPase agentsUS7481759Aug 2, 2002Jan 27, 2009Cardiac Pacemakers, Inc.Systems and methods for treatment of coronary artery diseaseUS8934968Jul 18, 2007Jan 13, 2015Cardiac Pacemakers, Inc.Neurostimulation and coronary artery disease treatmentUS20030036773 *Aug 2, 2002Feb 20, 2003Whitehurst Todd K.Systems and methods for treatment of coronary artery diseaseUS20040106954 *Nov 14, 2003Jun 3, 2004Whitehurst Todd K.Treatment of congestive heart failureUS20040248080 *Mar 16, 2004Dec 9, 2004The General Hospital CorporationMethods for screening HIF like ouabain-resistant Na+-K+-ATPase agentsUS20080021503 *Jul 18, 2007Jan 24, 2008Cardiac Pacemakers, Inc.Neurostimulation and coronary artery disease treatment* Cited by examinerClassifications U.S. Classification514/25, 536/5International ClassificationA61K38/00, C07K14/47Cooperative ClassificationA61K38/00, C07K14/4703European ClassificationC07K14/47A1ALegal EventsDateCodeEventDescriptionJul 23, 2001FPAYFee paymentYear of fee payment: 4Aug 9, 2005FPAYFee paymentYear of fee payment: 8Sep 14, 2009REMIMaintenance fee reminder mailedFeb 10, 2010LAPSLapse for failure to pay maintenance feesMar 30, 2010FPExpired due to failure to pay maintenance feeEffective date: 20100210RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services